Navigation Links
Maxygen Reports Third Quarter 2007 Financial Results
Date:11/1/2007

rug discovery and development may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. http://www.maxygen.com

Forward-Looking Statements

This news release contains forward-looking statements about our research and business prospects, including those relating to our ability to develop any human therapeutic products suitable for commercialization; our ability or plans, or the plans of our collaborators, to commence or continue the preclinical or clinical development of any of our product candidates, including MAXY-G34, MAXY-alpha and MAXY-VII, and the timing and status of any such development; whether any of our product candidates will exhibit improved properties in humans as compared to currently marketed drugs and whether these products, if commercialized, will be competitive in their relevant markets; and our liquidity and future financial performance. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Among other things these risks and uncertainties include, but are not limited to, changing research and business priorities of Maxygen and/or its collaborators, the inherent uncertainties of pharmaceutical research and drug development, our ability to develop human therapeutic drugs in an increasingly competitive biotechnology industry and the uncertain timing of such development, the development of superior products by competitors, and our ability to establish and maintain our research and commercialization collaborations and manufacturing arrangements. These and other risk factors are more fully discussed in our Form 10-K for the year ended December 31, 2006, including under the caption "Risk Factors," and in our other periodic SEC reports, all of which are available from Max
'/>"/>

SOURCE Maxygen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... led by Professor Andre Geim, a recipient of the 2010 ... a flow of electrons can magnetise graphene. ... potentially huge breakthrough in the field of spintronics. Spintronics ... spin of the electron, in addition to its fundamental electric ...
... IRVINE, Calif., April 15, 2011 CryoLife, Inc. (NYSE: ... and cardiovascular tissue processing company, today announced it has ... of Cardiogenesis Corporation ("Cardiogenesis") to acquire only 49.9 percent ... On April 14, 2011, Cardiogenesis, CryoLife and CryoLife,s wholly-owned ...
... Therapeutics, a company that manufactures novel blood plasma-based biomaterials ... on a Series A financing it will use to ... early clinical validation for the Company,s first products. ... Capital Partners, a private investment firm that invests in ...
Cached Biology Technology:New spin on graphene 2CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 2CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 3CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 4CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 5CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 6CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 7Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... & Science University researchers have identified some of the ... caused by multiple sclerosis (MS), complications of premature birth, ... clues about why the nervous system fails to repair ... of brain damage could be reversed. The research is ...
... information can be processed unconsciously when the area of ... temporarily shut down, according to research at Rice University ... Oct. 31 in the Proceedings of the National Academy ... has more than one pathway along which visual information ...
... identified some of the key factors that prevent the ... complications of premature birth, and other diseases and conditions. ... system fails to repair itself and suggest ways that ... reversed. The research is published in the August edition ...
Cached Biology News:Molecular Partners Required For Appropriate Neuronal Gene Repression 2Molecular Partners Required For Appropriate Neuronal Gene Repression 3Molecular Partners Required For Appropriate Neuronal Gene Repression 4Out of sight, out of mind? Not necessarily 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 3OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 4
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
... a synthetic peptide whose sequence is from the C-terminal end of the ... extends from amino acids 429 to 448 of RAR*. The sequence ... - V - S - P - S - S - V ... - Q - S - P - L - L - Q ...
... The ELx50 is a fast and versatile ... with our patented Dual-ActionTM 16-channel manifold. This ... the dispense and aspiration manifolds for overfill ... and 384-well formats. The problem of fitting ...
... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
Biology Products: